ALAMEDA, Calif.--(BUSINESS WIRE)--
BioTime, Inc. (NYSE MKT: BTX) announced today that it will be holding
its annual Investor Day providing company updates at the Harvard Club in
New York City. The presentations will be available on the company
Thomas Okarma, M.D., Ph.D., President and CEO of Asterias
Biotherapeutics Inc., will present a summary of Asterias, a new
subsidiary of BioTime. Asterias recently acquired Geron Corporation’s
human embryonic stem cell assets, as well as certain assets from
BioTime, including rights to use certain human embryonic stem cell lines
developed by BioTime’s subsidiary ES Cell International Pte Ltd.,
minority stakes in two of BioTime’s other subsidiaries, and BioTime
William Tew, Ph.D., BioTime’s Chief Commercial Officer will provide an
update on the development of Renevia™. In his presentation, Dr.
Tew will announce that enrollment in a safety trial evaluating Renevia™,
a proprietary injectable matrix designed to facilitate the stable
engraftment of transplanted cells, is complete and the initial ten
subjects who each received one subcutaneous injection of Renevia™
have been followed for three weeks after treatment and to date, Renevia™
has been well-tolerated by all patients with no serious adverse events.
BioTime will also describe new work using BioTime’s HyStem®
technology to develop 3D cell culture platforms for improved methods of
screening new anti-cancer drug candidates in a project funded by a
research grant from the National Institutes of Health.
Charles S. Irving, Ph.D., the CEO of BioTime’s subsidiary Cell Cure
Neurosciences Ltd. will provide an update on the development of OpRegen®.
In his presentation, Dr. Irving will describe the unmet medical needs
and markets for the treatment of the dry form of age-related macular
degeneration (AMD), and the advantages of Cell Cure’s OpRegen®
which has been produced from human embryonic stem cells in culture
conditions free of animal products, eliminating the need for designating
the product as a xenotransplantation therapeutic. Dr. Irving’s
presentation will contain assessments of Cell Cure’s approach by key
opinion leaders in the fields of macular degeneration and human
embryonic stem cell research. Dr. Irving will describe the progress of
the ongoing preclinical studies which are expected to lead to regulatory
filings for the initiation of human clinical trials in 2014.